# Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)

> **NCT00525668** · PHASE1,PHASE2 · COMPLETED · sponsor: **Charite University, Berlin, Germany** · enrollment: 120 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** epigallocatechin-gallate (Sunphenon)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00525668
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2021-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00525668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00525668, "Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00525668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*